This post was originally published on this site
“We are exploring different options,” Ruud Dobber, executive vice president and president, BioPharmaceuticals Business Unit, told Reuters, referring to the vaccines business.
“Before year-end, we will have more clarity… if you ask me, is the vaccine businesses a sustainable business for AstraZeneca for the next five or 10 years, that big strategic question is under discussion.”
